Analytical Transparency
Each PRG compound is tested for purity and identity under EU analytical standards.
COA documentation — Coming soon — and can be provided upon request with your order.
Skip to product information
SS-31 – High Purity Mitochondrial Research Peptide (50mg per vial)
€150,00
Shipping calculated at checkout.
Overview
SS-31 peptide has been FDA-approved in 2025 for treating Barth syndrome, a rare mitochondrial disorder, by improving cardiac function and exercise tolerance in affected patients.
In clinical trials, SS-31 peptide demonstrates potential to alleviate symptoms of primary mitochondrial diseases, including fatigue and muscle weakness, by enhancing mitochondrial bioenergetics.
Clinical Research Settings and Benefits
For patients with heart failure, SS-31 shows promise in reducing cardiac ischemia-reperfusion injury and improving overall heart function through mitochondrial stabilization.
SS-31 may benefit individuals with renal diseases by protecting against kidney ischemia-reperfusion damage, potentially slowing progression of chronic kidney disease.
In neurodegenerative conditions like Alzheimer’s and Parkinson’s, preclinical and early clinical data suggest SS-31 could mitigate neuronal damage by reducing oxidative stress in mitochondria.
Aging-related frailty may be addressed by SS-31, as studies indicate it improves skeletal muscle function and reduces inflammation in elderly models.
SS-31 holds potential for treating orphan cardiomyopathies, where it supports mitochondrial integrity to enhance cardiac output and patient quality of life. Clinical trials have demonstrated that elamipretide can improve myocardial ischemia-reperfusion injury and reduce complications after cardiac surgery.
For cognitive decline associated with aging, SS-31’s ability to restore mitochondrial health may improve brain function and memory in clinical settings.
SS-31 not only protects mitochondrial function but also plays a role in regulating the apoptotic process. It promotes cell survival by inhibiting endogenous apoptotic signals and delaying cell apoptosis. This property makes Elamipretide show potential in the study of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease because these diseases are often accompanied by abnormal cell apoptosis.
In models of dry age-related macular degeneration, SS-31 has shown efficacy in preserving retinal function by targeting mitochondrial dysfunction in ocular cells.
Slow photoreceptor degeneration by preserving EZ (Ellipsoid Zone) integrity. Improve low-luminance vision and reduce GA (Geographic Atrophy) progression (though not statistically significant in Phase 2 primaries). Mitigate oxidative stress and apoptosis in RPE cells (Retinal Pigment Epithelium Cell), potentially delaying vision loss. Offer neuroprotection without cytotoxicity.
Overall, SS-31’s broad therapeutic potential extends to metabolic disorders, where it could enhance energy production and insulin sensitivity by optimizing mitochondrial efficiency.
Molecular Mechanism of Action
SS-31 peptide, a synthetic tetrapeptide, selectively targets mitochondria by binding to cardiolipin in the inner mitochondrial membrane through hydrophobic interactions with acyl chains and electrostatic interactions with phosphate head groups.
This binding concentrates SS-31 in the inner membrane, stabilizing cristae morphology and optimizing the organization of respiratory chain supercomplexes.
SS-31 peptide interacts with subunits of oxidative phosphorylation complexes, such as complex III (QCR2 and QCR6), complex IV (NDUA4), and complex V (ATPA and ATPB), near their cardiolipin-binding sites. These interactions enhance electron transport efficiency and reduce hydrogen peroxide production in mitochondria.
By binding to ADP/ATP translocase (ADT1) in its matrix-open state, SS-31 prevents proton leak through charge repulsion while improving ADP sensitivity and ATP export.
SS-31 also binds to creatine kinase S-type near cardiolipin-binding residues, supporting mitochondrial structural integrity and phosphocreatine energy buffering.
In fatty acid β-oxidation, SS-31 interacts with the trifunctional enzyme subunit ECHA near its active site, potentially rescuing proton leak in deficient models.
For 2-oxoglutarate metabolism, SS-31 binds to isocitrate dehydrogenase at sites that may regulate enzymatic activity and NADPH production via electrostatic effects.
Additional interactions with 2-oxoglutarate dehydrogenase complex subunits and aspartate aminotransferase suggest SS-31 modulates TCA cycle flux and redox homeostasis.
Overall, these molecular interactions reduce reactive oxygen species, improve bioenergetics, and mitigate mitochondrial dysfunction at the protein and membrane level.
SS-31 Product Description
-
Sequence: D-Arg-Tyr(2,6-diMe)-Lys-Phe
-
Molecular Formula: C₃₂H₄₉N₉O₅
-
Molecular Weight: 639.8 g/mol
-
PubChem CID: 11764719
-
CAS Number: 736992-21-5
-
Synonyms: elamipretide, MTP-131, Bendavia
-
Total Active Ingredient: 30 mg per vial
-
Shelf Life: 36 months
Learn more about SS-31 and its role in mitochondrial health and longevity research
SS-31 Structures:
Source PubChem
Product Usage
This item is supplied for research purposes only.
Peptide Storage
All information provided by PRG is for educational and informational purposes only.
Best Practices for Storing Peptides
To maintain the reliability of laboratory results, correct peptide storage is essential. Proper storage conditions help preserve peptide stability for years while protecting against contamination, oxidation, and breakdown. Although certain peptides are more sensitive than others, following these best practices will greatly extend their shelf life and structural integrity.
- Short-Term Storage (days to months): Keep peptides cool and protected from light. Temperatures below 4 °C (39 °F) are generally suitable. Lyophilized peptides often remain stable at room temperature for several weeks, but refrigeration is still preferred if use is not immediate.
- Long-Term Storage (months to years): Store peptides at –80 °C (–112 °F) for maximum stability. Avoid frost-free freezers, as defrost cycles can cause damaging temperature fluctuations.
- Minimize Freeze–Thaw Cycles: Repeated freezing and thawing accelerates degradation. Instead, divide peptides into aliquots before freezing.
Preventing Oxidation & Moisture Damage
Peptides can be compromised by exposure to moisture and air—especially immediately after removal from a freezer.
- Let the vial warm to room temperature before opening to prevent condensation.
- Keep containers sealed as much as possible, and if possible, reseal under a dry, inert gas such as nitrogen or argon.
- Amino acids like cysteine (C), methionine (M), and tryptophan (W) are particularly sensitive to oxidation.
Storing Peptides in Solution
Peptides in solution have a much shorter lifespan compared to lyophilized form and are prone to bacterial degradation.
- If storage in solution is unavoidable, use sterile buffers at pH 5–6.
- Prepare single-use aliquots to avoid repeated freeze–thaw cycles.
- Most peptide solutions are stable for up to 30 days at 4 °C (39 °F), but sensitive sequences should remain frozen when not in use.
Containers for Peptide Storage
Select containers that are clean, intact, chemically resistant, and appropriately sized for the sample.
- Glass vials: offer clarity, durability, and chemical resistance.
- Plastic vials: polystyrene (clear but less resistant) or polypropylene (translucent but chemically resistant).
- Peptides shipped in plastic vials may be transferred to glass for long-term storage if desired.
Regenesis Peptide Storage Quick Tips
- Keep peptides in a cold, dry, dark environment
- Avoid repeated freeze–thaw cycles
- Minimize exposure to air
- Protect from light
- Avoid storing in solution long term
- Aliquot peptides to match experimental needs